A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 17, 2023

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions

Advanced CancerMetastatic Solid TumorSolid Tumor

Interventions

DRUG

TACH101

Orally via capsules

Trial Locations (8)

NEXT Oncology, Fairfax

Sarah Cannon Research Institute, Orlando

Sarah Cannon Research Institute, Nashville

MD Anderson, Houston

NEXT Oncology, San Antonio

NEXT Oncology, Austin

Sarah Cannon Research Institute, Denver

UCI Health, Orange

All Listed Sponsors

lead

Tachyon Therapeutics, Inc.

INDUSTRY